This week, I'm looking for the third healthcare sector representative of six for my Ivy portfolio.

That healthcare sector includes ten industries all related to testing, diagnosing and treating what ails us. Healthcare industries are: biotechnology; diagnostics & research; drug manufacturers - major and - specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices; medical distribution; medical supplies.

Today I'm reviewing another large-cap drug manufacturer - major named Amgen Inc. Its trading ticker symbol is AMGN.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases.

The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc.

Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

I use three key data points to gauge the value of any dividend equity like AMGN:

(1) Price

(2) Dividends

(3) Returns

Besides those three, several other keys  will finally unlock an equity or fund in which to invest. Those first three primary keys, however, best tell whether a company has made, is making, and will make money.

AMGN Price

Amgen's price per share closed at $190.08 yesterday. A year ago its price was $186.67. Price rose $3.35 per share last year, or almost 1.8%.

Assuming Amgen's stock trades in the range  of $165 to $210 again this year, Amgen's recent $190.02 price could rise by $9.98 and go to $200.00 by late-February, 2020.

AMGN Dividends

Amgen's most recent Quarterly dividend was $1.45 declared in December and payable Friday, March 8.

That quarterly dividend equates to a  $5.80 annual payout and a yield of 3.05% at yesterday's $190.02 closing price.

Gains For AMGN?

Adding the $5.80 annual estimated dividend to my $9.98 estimated price upside shows a $15.78 potential gross annual gain, per share, which will be reduced by costs to trade those shares.

Say we put a little under $1,000.00 today at the $190.02 recent stock price; that would buy us 5 Amgen shares.

A $10 broker fee paid half at purchase and half at sale costs $2.00 per share.

Subtract that $2.00 brokerage cost from the estimated $15.78 gross annual gain leaves a net gain of $13.78 X 5 shares

= $68.90  or a nearly  7.00% net gain on a $950.10 investment.

Therefore,  AMGN now shows a possible net gain of 7% including a 3.05% dividend yield.

Twenty-three brokers cover this stock:

• Six say "buy" AMGN.
• Three say AMGN will "outperform" peers
• Fourteen say "hold" on to your AMGN shares.

Therefore, you can look at  Amgen Inc  and see it has made money, is making money, and could throw a net gain of 7% including a 3.05% dividend yield. It could be more, it could be less.

The above speculation is based on past year performance. The actual results remain to be seen to determine if Amgen Inc  is worth your time and money.